Dr Yves Fradet graduated from Laval University (Quebec, Canada) in 1981 and completed an oncology fellowship at the Memorial Sloan-Kettering Cancer Center, with Drs Willet Whitmore and Lloyd Old. In 1983 he founded, at the Laval University Cancer Research Center, a translational and clinical research laboratory  in urological cancers whose work are supported continuously for more than 30 years.

Dr Fradet still has a very active practice in uro-Oncology within the Urologic Oncology Section and the Urology Service at the CHU de Québec- Hôtel-Dieu de Québec where he has grouped a team of specialists among the most important in Canada including seven uro-oncologists, three of which are also holders of PhD.

He is a member of many national and international societies, including since 2001, the American Association of Genitourinary Surgeons in which he was invited to be part of the 75 members in America. More recently, he was appointed international honorary member of the Association of Academic European Urology, membership awarded to those who have had important influence on urology. Dr Fradet is often invited as a guest speaker at national and international meetings, as a visiting professor, and as a consultant to many organizations. He was the founding chairman of the Canadian Urologic Oncology Group from 1988 to 1995 and chairman of the Department of Surgery at Laval University from 2000 to 2008. He has authored over 330 publications and book chapters and more than 600 abstracts.

L'Hôtel-Dieu de Québec
10, rue McMahon
1853-1
Québec, Québec
Canada G1R 2J6
310 entries « 1 of 31 »

Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, Hamilton RJ, Davis MK, Karampatos S, Mian R, Delouya G, Fradet Y, Mukherjee S, Conen D, Chen-Tournoux A, Johnson C, Bessissow A, Dresser G, Hameed AK, Abdel-Qadir H, Sener A, Pal R, Devereaux PJ, Pinthus J, RADICAL PC Investigators

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.

Journal Article

J Urol, 203 (6), pp. 1109-1116, 2020, ISSN: 0022-5347.

Abstract | Links:

Levesque E, Labriet A, Hovington H, Allain EP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Audet-Walsh E, Simonyan D, Fradet Y, Lacombe L, Guillemette C

Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.

Journal Article

Br J Cancer, 122 (7), pp. 1068-1076, 2020, ISSN: 0007-0920.

Abstract | Links:

Lavallee E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F

Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration.

Journal Article

Eur Urol Focus, 5 (6), pp. 998-1006, 2019.

Abstract | Links:

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up.

Journal Article

Ann Oncol, 30 (6), pp. 970-976, 2019, ISSN: 0923-7534.

Abstract | Links:

Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, Dionne N, Delouya G, Kougioumoutzakis A, Sirois J, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Zorn KC, Fradet Y, Saad F, Taussky D, Trudel D

Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate.

Journal Article

Radiat Oncol, 14 (1), pp. 60, 2019.

Abstract | Links:

Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, Lapuk A, Chua MLK, Heisler LE, Foucal A, Fox NS, Fraser M, Bhandari V, Shiah YJ, Guan J, Li J, Orain M, Picard V, Hovington H, Bergeron A, Lacombe L, Fradet Y, Tetu B, Liu S, Feng F, Wu X, Shao YW, Komor MA, Sahinalp C, Collins C, Hoogstrate Y, de Jong M, Fijneman RJA, Fei T, Jenster G, van der Kwast T, Bristow RG, Boutros PC, He HH

Widespread and Functional RNA Circularization in Localized Prostate Cancer.

Journal Article

Cell, 176 (4), pp. 831-843.e22, 2019, ISSN: 0092-8674.

Abstract | Links:

Rouleau M, Lemire F, Dery M, Theriault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guerette D, Pouliot F

Discordance between testosterone measurement methods in castrated prostate cancer patients.

Journal Article

Endocr Connect, 8 (2), pp. 132-140, 2019, ISSN: 2049-3614.

Abstract | Links:

Kulkarni GS, Black PC, Sridhar SS, Kapoor A, Zlotta AR, Shayegan B, Rendon R, Chung P, Van Der Kwast T, Alimohamed N, Fradet Y, Kassouf W

Canadian Urological Association guideline: Muscle-invasive bladder cancer.

Journal Article

Can Urol Assoc J, pp. 230-238, 2019, ISSN: 1911-6470.

| Links:

Gevariya N, Besancon M, Robitaille K, Picard V, Diabate L, Alesawi A, Julien P, Fradet Y, Bergeron A, Fradet V

Omega-3 fatty acids decrease prostate cancer progression associated with an anti-tumor immune response in eugonadal and castrated mice.

Journal Article

Prostate, 79 (1), pp. 9-20, 2019, ISSN: 0270-4137.

Abstract | Links:

Levesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C

A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer.

Journal Article

Cancer Epidemiol Biomarkers Prev, 28 (4), pp. 701-706, 2019, ISSN: 1055-9965.

Abstract | Links:

310 entries « 1 of 31 »
Signaler des ajouts ou des modifications

Active projects

  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., Subvention, Société de recherche sur le cancer, Compétition GRePEC (SRC/FRSQ/MDEIE), from 2012-10-01 to 2020-08-31
  • Prebiotics to enhance immunotherapy response in bladder cancer, Subvention, The W. Garfield Weston Foundation, 2018 Proof-of-Principle Grant Call, from 2019-01-01 to 2020-07-31
  • Stromal Gene Expression Predicts And May Drive Metastasis in Prostate Cancer, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2017-04-01 to 2022-03-31
  • Toward nutritional and epigenomic interventions in prostate cancer prevention and management, Subvention, Instituts de recherche en santé du Canada, Fonctionnement: Subvention de promotion de l’impact - CCREES, from 2017-10-01 to 2020-09-30

Recently finished projects

  • (FRSQ 83876)Targeting PD-1 and TIGIT pathways for the immunotherapy of bladder cancer, Subvention, Association canadienne d'urologie, from 2018-11-23 to 2019-11-22
  • (FRSQ 83897) Inducing prostate tumor eosinophilia to favor prostate cancer immunotherapy , Subvention, Canadian Urological Association Scholarship Foundation, CUA Astellas Research Grant Program 2017, from 2018-06-19 to 2019-06-18
  • (FRSQ 84899) Financement de la phase 1 du projet de recherche DPX-SurMAGE, Subvention, Fondation du CHU de Québec, from 2019-03-25 to 2020-03-24
  • Combination of Wnt-ß-catenin, androgen receptor and PD-1 inhibition for the therapy of bladder cancer, Subvention, Cancer de la vessie Canada, Research Grant Program 2017, from 2018-01-01 to 2018-12-31
  • Development of a urine-based prostate cancer cell bioluminescence imaging nanotechnology for single cell transcriptional characterization, Subvention, Société de recherche sur le cancer, Subvention de fonctionnement, from 2016-09-01 to 2018-08-31
  • Development of bladder cancer immunotherapy., Subvention, L'Institut de recherche de la Société canadienne du cancer, Subventions pour un impact, from 2013-02-01 to 2019-01-31
  • Effects of the Leucocytic Infiltration of Intraductal Carcinoma of the Prostate, Partenariat, Société de recherche sur le cancer, Subvention de fonctionnement, from 2017-09-01 to 2019-08-31
  • Effet de la thérapie combinant un anti-PD-1 et le tasquinimod pour le traitement du cancer de la prostate, Subvention, Université Laval - Soutien à la recherche, from 2018-05-01 to 2019-04-30
  • Enhancing bladder cancer immunotherapy efficacy in men using bicalutamide, Subvention, Société de recherche sur le cancer, from 2018-12-01 to 2019-11-30
  • Tranexamic acid during cystectomy trial (TACT), Subvention, Instituts de recherche en santé du Canada, Subvention de fonctionnement, from 2015-07-01 to 2018-06-30
Data provided by the Université Laval research projects registery